Net loss narrowed in H1 2024 as revenue grew and costs were reduced, aided by a 3 MSEK capital raise. Outlook for Q4 is positive if procurement processes proceed, with continued focus on immuno-oncology clients.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.